These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16691072)

  • 1. Baseline HIV RNA and the when to start question: time to stop asking this question?
    Mussini C
    AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072
    [No Abstract]   [Full Text] [Related]  

  • 2. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
    Abbas UL; Mellors JW
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to start, when to STI (or, groping for the golden moment).
    Mascolini M
    IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 7. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
    Rodés B; Toro C; Jiménez V; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):e19-21. PubMed ID: 15983906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stopping antiretroviral therapy in 'prematurely treated' HIV-1-infected children with full viral supression is safe.
    Reula ES; León-Leal JA; Leal M; Obando I; Muñoz-Fernández A
    AIDS; 2006 Jan; 20(2):307-9. PubMed ID: 16511434
    [No Abstract]   [Full Text] [Related]  

  • 9. Intermittent antiretroviral therapy in patients with controlled HIV infection.
    Marchou B; Tangre P; Charreau I; Izopet J; Girard PM; May T; Ragnaud JM; Aboulker JP; Molina JM;
    AIDS; 2007 Feb; 21(4):457-66. PubMed ID: 17301564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

  • 11. Strategies of HIV management--when to start.
    Youle M
    AIDS; 2002; 16 Suppl 4():S145-9. PubMed ID: 12699011
    [No Abstract]   [Full Text] [Related]  

  • 12. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stopping antiretroviral therapy: easier said than done.
    Hull M; Harris M; Montaner JS
    AIDS; 2007 Aug; 21(13):1817-8. PubMed ID: 17690582
    [No Abstract]   [Full Text] [Related]  

  • 14. Interleukin 2 and HIV RNA Levels.
    Go R; Steigbigel R
    Arch Intern Med; 2007 Oct; 167(19):2144-5; author reply 2145. PubMed ID: 17954814
    [No Abstract]   [Full Text] [Related]  

  • 15. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.
    Barbour JD; Hecht FM; Little SJ; Markowitz M; Daar ES; Kelleher AD; Routy JP; Campbell TB; Rosenberg ES; Segal MR; Weidler J; Grant RM
    AIDS; 2006 Oct; 20(16):2123-5. PubMed ID: 17053362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

  • 19. When to start antiretroviral therapy? NA-ACCORD stimulates the debate.
    Gallant JE
    AIDS Read; 2009 Feb; 19(2):49-50, 61. PubMed ID: 19271328
    [No Abstract]   [Full Text] [Related]  

  • 20. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.